Breaking News, Promotions & Moves

Kyverna Therapeutics Appoints New CEO

Warner Biddle succeeds Peter Maag as Chief Executive Officer and a member of the Board of Directors.

Author Image

By: Charlie Sternberg

Associate Editor

Kyverna Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, has appointed Warner Biddle as its Chief Executive Officer (CEO) and a member of its Board of Directors, succeeding Peter Maag, Ph.D., who has resigned from his role as CEO and a member of the Board, effective immediately.   Kyverna also appointed Christi Shaw to its Board of Directors. Shaw succeeds Brian Kotzin, M.D., who has decided to s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters